5/17/2023 0 Comments Anti dm1 antibody![]() to summarize the development trend and research hotspots of ADCs. The authors will map from national distribution, drug types, drug_targets, cancer classification, clinical stages, etc. According to the comprehensive analysis, the research output of ADCs is increasing year by year, covering all regions, including the United_States, Europe, and Asia. The top 10 countries included the United_States, Spain, France, the United Kingdom, Belgium, Canada, Italy, China, South Korea, and Australia. The top 5 countries in the central ranking are the United_States, Britain, Italy, France, and Spain. According to the analysis, the top 5 countries in the number of documents are the United_States, China, Japan, Italy, and the United Kingdom. Globally, 14 ADCs have been approved by the United_States Food and Drug Administration (FDA) for the treatment of various tumor indications, including disitamab vedotin (RC-48) independently developed by RemeGen Co. Scientists are beginning to explore the efficacy of individual drugs in multiple indications and combination therapeutic strategy is also becoming a future research direction. This article had the highest centrality (centrality=0.21) suggesting that the results of this trial are leading the way for future studies in the field of ADCs. tumor xenograft model (PDXS) with ERBB2 amplification and mutation (S310F) has a more significant and lasting effect than that of T-DM1 alone in inducing tumor regression. future: The innovation of ADCs technology and the joint application strategy is still the favored breakthrough points in the field of cancer in the future.To provide reference and help for the application of ADCs in targeted cancer therapy the authors analyzed this research status development trend and future hotspots of ADCs worldwide. The authors used CiteSpace to conduct a systematic search and analysis of ADCs literature within the WoS core database from 2012-2022. ![]() how: The results showed that BV DS-8201a sacituzumab govitecan (IMMU-132) and Ado-trastuzumab emtansine (TDM1) were the most studied drugs in the field with BV being the most studied drug in clinical trials.These issues will be the main focus of ADC in future research. what: Frontiers in Oncology 10.3389/fonc.2022.1039882 in-depth research and clinical applications of ADCs, this study provides a reference value.from the The National Institutes of Health and the National Library ofItaly University, China have published the article: Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis, in the Journal: (JOURNAL) of March/21,/2022
0 Comments
Leave a Reply. |